Cambridge Investment Research Advisors
RVMD icon

Cambridge Investment Research Advisors’s Revolution Medicines RVMD Stock Holding History

Cambridge Investment Research Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.97M Sell
15,839
-586
-4% -$85.6K 0.01% 1393
2026
Q1 		$1.6M Buy
+16,425
New +$1.66M ﹤0.01% 1782
2025
Q1 		– Sell
-8,358
Closed -$366K – 3612
2024
Q4 		$366K Buy
+8,358
New +$422K ﹤0.01% 2672

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Cambridge Investment Research Advisors's RVMD Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its Revolution Medicines (RVMD) stake by 3.6% in Q2 2026, selling an estimated $85.6K and leaving 15,839 shares worth $2.97M. The position accounts for 0.01% of the portfolio, ranked #1393.

Cambridge Investment Research Advisors first reported a position in RVMD in Q4 2024 and has held it in 3 quarters since. 694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Cambridge Investment Research Advisors held 15,839 shares of Revolution Medicines worth $2.97M as of Q2 2026.
  • Cambridge Investment Research Advisors sold 586 Revolution Medicines shares in Q2 2026, an estimated $85.6K.
  • Revolution Medicines made up 0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1393 holding.
  • Cambridge Investment Research Advisors first reported a position in Revolution Medicines in Q4 2024 and has held it in 3 quarters since.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.